



(51) International Patent Classification:

A61P 35/00 (2006.01) C07D 498/04 (2006.01)

C07D 487/04 (2006.01) A61K 31/553 (2006.01)

(21) International Application Number:

PCT/US2020/063272

(22) International Filing Date:

04 December 2020 (04.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/946,586 11 December 2019 (11.12.2019) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **BOULET, Serge Louis**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **FORTNER, Kevin Charles**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **GUO, Deqi**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **HYMAN, David Michael**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **PENG, Sheng-Bin**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **SI, Chong**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agent: **MCGRAW, Elizabeth A.** et al.; Eli Lilly and Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,

KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: KRAS G12C INHIBITORS



(57) Abstract: The present invention provides compounds of the formula: where R₁, R₂, R₃, R₄, R₅, A, B, and Y are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and salts for treating patients for cancer.

